<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周三发布给投资者的研究报告中，TD Cowen 的股票研究人员将其目标价格从 190.00 美元下调至 120.00 美元，Benzinga 报道。该公司目前对该股票维持 “买入” 评级。TD Cowen 的目标价格意味着该股票当前价格有 64.68% 的潜在上涨空间。</p>
<p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
<ul>
<li>中型股奇迹：3 只在 5 月超越销售预期的股票</li>
</ul>
<p>其他一些分析师最近也对 TMDX 发布了报告。Piper Sandler 将 TransMedics Group 的目标价格从 160.00 美元下调至 120.00 美元，并在周三的报告中给予该公司 “增持” 评级。Oppenheimer 在周三的报告中将 TransMedics Group 的评级从 “跑赢大盘” 下调至 “市场表现”。Needham &amp; Company LLC 在周三的报告中将 TransMedics Group 的目标价格从 174.00 美元下调至 142.00 美元，并给予该公司 “买入” 评级。Stifel Nicolaus 在周三的报告中将 TransMedics Group 的目标价格从 130.00 美元下调至 85.00 美元，并给予该公司 “持有” 评级。最后，摩根大通在 2 月 25 日的报告中将 TransMedics Group 的目标价格从 114.00 美元上调至 149.00 美元，并给予该股票 “中性” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，六位分析师则给予了 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 137.40 美元。</p>
<p><strong>阅读我们关于 TransMedics Group 的最新股票报告</strong></p>
<h2>TransMedics Group 价格表现</h2>
<ul>
<li>3 只在 2025 年表现优异的医疗科技股票</li>
</ul>
<p>在周三的交易中，TMDX 下跌 22.06 美元，达到 72.87 美元。该公司的股票交易量为 6,872,613 股，而其平均交易量为 962,752 股。该公司的速动比率为 6.59，流动比率为 7.14，债务与股本比率为 1.06。该公司有 50 日简单移动平均线为 116.57 美元，200 日简单移动平均线为 125.96 美元。TransMedics Group 的 1 年最低价为 70.00 美元，1 年最高价为 156.00 美元。该公司的市值为 25.2 亿美元，市盈率为 14.87，贝塔值为 2.07。</p>
<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最后一次公布季度财报是在 5 月 5 日，报告显示该公司每股收益（EPS）为 0.30 美元，低于分析师共识预期的 0.62 美元，差额为 0.32 美元。该公司季度收入为 1.7393 亿美元，而分析师预期为 1.7448 亿美元。TransMedics Group 的股本回报率为 30.17%，净利润率为 31.43%。该公司的季度收入同比增长 21.2%。在去年同期，该公司每股收益为 0.70 美元。整体来看，分析师预计 TransMedics Group 在当前年度的每股收益为 2.48 美元。</p>
<h2>TransMedics Group 的内部交易</h2>
<ul>
<li>3 只高增长股票，交易者喜爱，投资者应关注</li>
</ul>
<p>在相关消息中，内部人士 Anil P. Ranganath 在 3 月 2 日的交易中出售了 864 股 TransMedics Group 的股票，出售价格为 139.12 美元，总价值为 120,199.68 美元。出售完成后，该内部人士持有该公司 13,091 股股票，价值约为 1,821,219.92 美元。此交易代表其持股减少了 6.19%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，首席财务官 Gerardo Hernandez 在 3 月 4 日的交易中出售了 7,236 股 TransMedics Group 的股票，出售价格为 147.21 美元，总交易额为 1,065,211.56 美元。出售完成后，首席财务官持有该公司 14,689 股股票，价值为 2,162,367.69 美元。此交易代表其持股减少了 33.00%。该交易的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售价值 2,353,002 美元的 16,205 股公司股票。公司内部人士持有公司股票的 6.90%。</p>
<h2>TransMedics Group 的机构交易</h2>
<p>机构投资者最近增加或减少了对该股票的持股。加拿大皇家银行在第一季度将其在 TransMedics Group 的持股增加了 47.9%。加拿大皇家银行目前持有该公司 26,582 股股票，价值 1,788,000 美元，此前在上一季度增加了 8,604 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 TransMedics Group 的持股增加了 4.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有该公司 19,525 股股票，价值 1,314,000 美元，此前在上一季度增加了 868 股。高盛集团在第一季度将其在 TransMedics Group 的持股增加了 20.6%。高盛集团目前持有该公司 507,510 股股票，价值 34,145,000 美元，此前在上一季度增加了 86,721 股。拉塞尔投资集团在第二季度将其在 TransMedics Group 的持股增加了 13.5%。拉塞尔投资集团目前持有该公司 7,901 股股票，价值 1,059,000 美元，此前在上一季度增加了 938 股。最后，M&amp;T 银行在第二季度收购了 TransMedics Group 的新头寸，价值 209,000 美元。机构投资者和对冲基金持有该公司 99.67% 的股票。</p>
<h2>影响 TransMedics Group 的关键头条新闻</h2>
<p>以下是本周影响 TransMedics Group 的关键新闻故事：</p>
<ul>
<li>积极情绪：Needham 下调了目标价但仍持建设性态度——Needham 将目标价从$174 下调至$142，并维持 “买入” 评级，暗示如果基本面重新加速，将有显著的上涨空间。Needham 目标价下调</li>
<li>积极情绪：Piper Sandler 尽管将目标价下调至$120，但仍保持超配立场，表明一些经纪人仍然看到中期上涨空间。Piper Sandler 目标价变动</li>
<li>中性情绪：营收增长保持稳定——第一季度营收同比增长约 21%，达到$173.93M，主要受 OCS 需求和物流增长推动，表明尽管盈利能力下滑，商业吸引力仍在持续。Zacks 营收覆盖</li>
<li>消极情绪：每股收益和利润率大幅不及预期——TMDX 报告每股收益为$0.30，而市场共识约为$0.62，并指出利润率承压；市场对盈利和盈利能力恶化进行了惩罚。财报发布</li>
<li>消极情绪：分析师语气变得更加谨慎——Oppenheimer 将 TMDX 评级从 “跑赢大盘” 下调至 “市场表现”，Stifel 将目标价从$130 下调至$85，并转为 “持有”，增加了卖压。Oppenheimer 下调 Stifel 目标价下调</li>
<li>消极情绪：FY26 营收指引范围（$727M–$757M）接近华尔街的预期，可能被解读为对预期的谨慎，留下较少的短期上涨空间，并加大对利润率和执行力的关注。PR Newswire 指引</li>
</ul>
<h2>TransMedics Group 公司简介</h2>
<p>(获取免费报告)</p>
<p>TransMedics Group, Inc 是一家总部位于马萨诸塞州安多佛的医疗设备公司，专注于用于移植的先进器官保存和运输系统。该公司的旗舰技术，器官护理系统（OCS），在运输过程中保持供体器官处于接近生理的温暖跳动状态，旨在延长保存时间并改善移植后的结果。TransMedics 的解决方案满足了移植中一个关键需求，通过减少缺血损伤和扩大供体器官池。</p>
<p>TransMedics 目前市场上有两个商业可用的 OCS 平台。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 TransMedics Group 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 TransMedics Group 吗？</h2>
<p>在考虑 TransMedics Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 TransMedics Group 并不在名单上。</p>
<p>虽然 TransMedics Group 目前在分析师中拥有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TMDX

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>TD Cowen 将 TransMedics Group (NASDAQ:TMDX) 的目标价从 190.00 美元下调至 120.00 美元，同时维持 “买入” 评级。其他分析师也调整了他们的目标价，Piper Sandler 和 Needham & Company LLC 分别设定目标价为 120.00 美元和 142.00 美元。该股票目前交易价格为 72.87 美元，较新目标价有 64.68% 的潜在上涨空间。公司报告的季度每股收益为 0.30 美元，低于预期，市值为 25.2 亿美元</p>

<p>TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price target cut by equities researchers at TD Cowen from $190.00 to $120.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. TD Cowen's price target would indicate a potential upside of 64.68% from the stock's current price.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周三发布给投资者的研究报告中，TD Cowen 的股票研究人员将其目标价格从 190.00 美元下调至 120.00 美元，Benzinga 报道。该公司目前对该股票维持 “买入” 评级。TD Cowen 的目标价格意味着该股票当前价格有 64.68% 的潜在上涨空间。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股奇迹：3 只在 5 月超越销售预期的股票</li>
</ul>
</div><p>A number of other analysts also recently issued reports on TMDX. Piper Sandler cut their price target on shares of TransMedics Group from $160.00 to $120.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday. Oppenheimer downgraded shares of TransMedics Group from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Wednesday. Needham &amp; Company LLC cut their price target on shares of TransMedics Group from $174.00 to $142.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday. Stifel Nicolaus cut their price target on shares of TransMedics Group from $130.00 to $85.00 and set a &#34;hold&#34; rating for the company in a report on Wednesday. Finally, JPMorgan Chase &amp; Co. raised their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $137.40.</p>
<div class="lb-trans"><p>其他一些分析师最近也对 TMDX 发布了报告。Piper Sandler 将 TransMedics Group 的目标价格从 160.00 美元下调至 120.00 美元，并在周三的报告中给予该公司 “增持” 评级。Oppenheimer 在周三的报告中将 TransMedics Group 的评级从 “跑赢大盘” 下调至 “市场表现”。Needham &amp; Company LLC 在周三的报告中将 TransMedics Group 的目标价格从 174.00 美元下调至 142.00 美元，并给予该公司 “买入” 评级。Stifel Nicolaus 在周三的报告中将 TransMedics Group 的目标价格从 130.00 美元下调至 85.00 美元，并给予该公司 “持有” 评级。最后，摩根大通在 2 月 25 日的报告中将 TransMedics Group 的目标价格从 114.00 美元上调至 149.00 美元，并给予该股票 “中性” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，六位分析师则给予了 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 137.40 美元。</p>
</div><p><strong>Read Our Latest Stock Report on TransMedics Group</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TransMedics Group 的最新股票报告</strong></p>
</div><h2>TransMedics Group Price Performance</h2>
<div class="lb-trans"><h2>TransMedics Group 价格表现</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只在 2025 年表现优异的医疗科技股票</li>
</ul>
</div><p>TMDX traded down $22.06 during trading on Wednesday, reaching $72.87. The company's stock had a trading volume of 6,872,613 shares, compared to its average volume of 962,752. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The firm has a fifty day simple moving average of $116.57 and a two-hundred day simple moving average of $125.96. TransMedics Group has a 1 year low of $70.00 and a 1 year high of $156.00. The company has a market cap of $2.52 billion, a price-to-earnings ratio of 14.87 and a beta of 2.07.</p>
<div class="lb-trans"><p>在周三的交易中，TMDX 下跌 22.06 美元，达到 72.87 美元。该公司的股票交易量为 6,872,613 股，而其平均交易量为 962,752 股。该公司的速动比率为 6.59，流动比率为 7.14，债务与股本比率为 1.06。该公司有 50 日简单移动平均线为 116.57 美元，200 日简单移动平均线为 125.96 美元。TransMedics Group 的 1 年最低价为 70.00 美元，1 年最高价为 156.00 美元。该公司的市值为 25.2 亿美元，市盈率为 14.87，贝塔值为 2.07。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.48 million. TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.The firm's quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 EPS. As a group, analysts anticipate that TransMedics Group will post 2.48 EPS for the current year.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最后一次公布季度财报是在 5 月 5 日，报告显示该公司每股收益（EPS）为 0.30 美元，低于分析师共识预期的 0.62 美元，差额为 0.32 美元。该公司季度收入为 1.7393 亿美元，而分析师预期为 1.7448 亿美元。TransMedics Group 的股本回报率为 30.17%，净利润率为 31.43%。该公司的季度收入同比增长 21.2%。在去年同期，该公司每股收益为 0.70 美元。整体来看，分析师预计 TransMedics Group 在当前年度的每股收益为 2.48 美元。</p>
</div><h2>Insider Transactions at TransMedics Group</h2>
<div class="lb-trans"><h2>TransMedics Group 的内部交易</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只高增长股票，交易者喜爱，投资者应关注</li>
</ul>
</div><p>In related news, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $120,199.68. Following the completion of the sale, the insider owned 13,091 shares in the company, valued at approximately $1,821,219.92. This trade represents a 6.19% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CFO Gerardo Hernandez sold 7,236 shares of TransMedics Group stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the completion of the sale, the chief financial officer owned 14,689 shares of the company's stock, valued at $2,162,367.69. This trade represents a 33.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 16,205 shares of company stock worth $2,353,002 in the last three months. Company insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Anil P. Ranganath 在 3 月 2 日的交易中出售了 864 股 TransMedics Group 的股票，出售价格为 139.12 美元，总价值为 120,199.68 美元。出售完成后，该内部人士持有该公司 13,091 股股票，价值约为 1,821,219.92 美元。此交易代表其持股减少了 6.19%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，首席财务官 Gerardo Hernandez 在 3 月 4 日的交易中出售了 7,236 股 TransMedics Group 的股票，出售价格为 147.21 美元，总交易额为 1,065,211.56 美元。出售完成后，首席财务官持有该公司 14,689 股股票，价值为 2,162,367.69 美元。此交易代表其持股减少了 33.00%。该交易的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士已出售价值 2,353,002 美元的 16,205 股公司股票。公司内部人士持有公司股票的 6.90%。</p>
</div><h2>Institutional Trading of TransMedics Group</h2>
<div class="lb-trans"><h2>TransMedics Group 的机构交易</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in shares of TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock worth $1,314,000 after acquiring an additional 868 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company's stock worth $1,059,000 after acquiring an additional 938 shares in the last quarter. Finally, M&amp;T Bank Corp acquired a new position in shares of TransMedics Group in the second quarter worth $209,000. Institutional investors and hedge funds own 99.67% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持股。加拿大皇家银行在第一季度将其在 TransMedics Group 的持股增加了 47.9%。加拿大皇家银行目前持有该公司 26,582 股股票，价值 1,788,000 美元，此前在上一季度增加了 8,604 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 TransMedics Group 的持股增加了 4.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有该公司 19,525 股股票，价值 1,314,000 美元，此前在上一季度增加了 868 股。高盛集团在第一季度将其在 TransMedics Group 的持股增加了 20.6%。高盛集团目前持有该公司 507,510 股股票，价值 34,145,000 美元，此前在上一季度增加了 86,721 股。拉塞尔投资集团在第二季度将其在 TransMedics Group 的持股增加了 13.5%。拉塞尔投资集团目前持有该公司 7,901 股股票，价值 1,059,000 美元，此前在上一季度增加了 938 股。最后，M&amp;T 银行在第二季度收购了 TransMedics Group 的新头寸，价值 209,000 美元。机构投资者和对冲基金持有该公司 99.67% 的股票。</p>
</div><h2>Key Headlines Impacting TransMedics Group</h2>
<div class="lb-trans"><h2>影响 TransMedics Group 的关键头条新闻</h2>
</div><p>Here are the key news stories impacting TransMedics Group this week:</p>
<div class="lb-trans"><p>以下是本周影响 TransMedics Group 的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Needham cut its price target but remains constructive — Needham lowered its target from $174 to $142 and kept a &#34;buy&#34; rating, implying substantial upside if fundamentals re-accelerate. Needham PT cut</li>
<li>Positive Sentiment: Piper Sandler also kept an overweight stance despite cutting its target to $120, signaling that some brokers still see medium-term upside. Piper Sandler PT change</li>
<li>Neutral Sentiment: Top-line growth remains intact — Q1 revenue rose ~21% year-over-year to $173.93M driven by OCS demand and logistics growth, indicating continued commercial traction even as profitability slipped. Zacks revenue coverage</li>
<li>Negative Sentiment: Material EPS and margin miss — TMDX reported $0.30 EPS vs. consensus ~$0.62 and noted margin pressure; markets penalize the earnings and the deterioration in profitability. Earnings release</li>
<li>Negative Sentiment: Analyst tone turned more cautious — Oppenheimer downgraded TMDX from &#34;outperform&#34; to &#34;market perform&#34; and Stifel cut its PT from $130 to $85 and moved to &#34;hold&#34;, increasing selling pressure. Oppenheimer downgradeStifel PT cut</li>
<li>Negative Sentiment: FY26 revenue guidance range ($727M–$757M) sits around Wall Street's view and may be read as cautious vs. expectations, leaving less near-term upside and amplifying focus on margins and execution. PR Newswire guidance</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Needham 下调了目标价但仍持建设性态度——Needham 将目标价从$174 下调至$142，并维持 “买入” 评级，暗示如果基本面重新加速，将有显著的上涨空间。Needham 目标价下调</li>
<li>积极情绪：Piper Sandler 尽管将目标价下调至$120，但仍保持超配立场，表明一些经纪人仍然看到中期上涨空间。Piper Sandler 目标价变动</li>
<li>中性情绪：营收增长保持稳定——第一季度营收同比增长约 21%，达到$173.93M，主要受 OCS 需求和物流增长推动，表明尽管盈利能力下滑，商业吸引力仍在持续。Zacks 营收覆盖</li>
<li>消极情绪：每股收益和利润率大幅不及预期——TMDX 报告每股收益为$0.30，而市场共识约为$0.62，并指出利润率承压；市场对盈利和盈利能力恶化进行了惩罚。财报发布</li>
<li>消极情绪：分析师语气变得更加谨慎——Oppenheimer 将 TMDX 评级从 “跑赢大盘” 下调至 “市场表现”，Stifel 将目标价从$130 下调至$85，并转为 “持有”，增加了卖压。Oppenheimer 下调 Stifel 目标价下调</li>
<li>消极情绪：FY26 营收指引范围（$727M–$757M）接近华尔街的预期，可能被解读为对预期的谨慎，留下较少的短期上涨空间，并加大对利润率和执行力的关注。PR Newswire 指引</li>
</ul>
</div><h2>TransMedics Group Company Profile</h2>
<div class="lb-trans"><h2>TransMedics Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.</p>
<div class="lb-trans"><p>TransMedics Group, Inc 是一家总部位于马萨诸塞州安多佛的医疗设备公司，专注于用于移植的先进器官保存和运输系统。该公司的旗舰技术，器官护理系统（OCS），在运输过程中保持供体器官处于接近生理的温暖跳动状态，旨在延长保存时间并改善移植后的结果。TransMedics 的解决方案满足了移植中一个关键需求，通过减少缺血损伤和扩大供体器官池。</p>
</div><p>TransMedics currently markets two commercially available OCS platforms.</p>
<div class="lb-trans"><p>TransMedics 目前市场上有两个商业可用的 OCS 平台。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 TransMedics Group 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TMDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 TransMedics Group 吗？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 TransMedics Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而 TransMedics Group 并不在名单上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TransMedics Group 目前在分析师中拥有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

TransMedics 集团（NASDAQ:TMDX）在 TD Cowen 的目标股价被下调至 120.00 美元